Rubidium-82

DRUG4 trials

Sponsors

Advanced Accelerator Applications, Timothy M. Bateman, MD, Cardiovascular Imaging Technologies, Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)

Conditions

Coronary Artery DiseaseHeart FailureICD PatientsIschemic CardiomyopathyMyocardial Blood Flow Reserve

Phase 2

18F-mFBG Imaging for Myocardial Sympathetic Innervation

RecruitingNCT06965621

Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)Heart Failure, ICD Patients, Ischemic Cardiomyopathy

Start: 2025-11-05End: 2026-12-30Target: 20Updated: 2026-07-01

Phase 3

Rubidium-82 PET and Tc-99m-MIBI SPET: A Head to Head Comparison

CompletedNCT01379677

Advanced Accelerator ApplicationsCoronary Artery Disease

Start: 2011-02-28End: 2013-11-30Updated: 2014-05-14

Phase 4

Characterization of Myocardial Blood Flow Measurements Using Lexiscan®™ (Regadenoson) (Lexiscan®™) Rubidium-82 Myocardial Perfusion PET: A Temporal-Dependency Investigation

CompletedNCT01919450

Timothy M. Bateman, MDMyocardial Blood Flow Reserve

Start: 2013-07-31End: 2016-04-30Updated: 2018-08-16

Unknown Phase

Impact of Coronary Artery Stenting on Quantitative Myocardial Blood Flow and Health Status

Cardiovascular Imaging TechnologiesCoronary Artery Disease

Start: 2019-12-23End: 2021-12-31Target: 75Updated: 2020-07-17